Riot Platforms, Inc. quarterly report, Q1 FY2012

Filing identity and reporting period

The supplied filing is AspenBio Pharma, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2012—not a Riot Platforms, Inc. filing. The company and filing-period metadata in the request therefore do not match the source text.

Financial results and condition

At March 31, 2012, cash and cash equivalents were $1.316 million and short-term investments were $562,000, totaling approximately $1.878 million in cash and liquid investments. Working capital was $437,000. Total assets were $6.367 million, total liabilities $4.257 million, and stockholders’ equity $2.110 million; accumulated deficit was $66.959 million. Notes and other obligations totaled $3.569 million, including $966,000 current and $2.603 million long-term. The company reported no income tax benefit for either comparison period.

Material changes and management commentary

Sales fell largely because the company had suspended antigen production and focused resources on product development; Q1 2012 also had no revenue recognized from the Novartis license agreement, which was terminated in November 2011. SG&A declined 25% to $1.205 million, and R&D declined 47% to $677,000, reflecting lower personnel, stock-compensation, investigational, and animal-product development costs. Gross margin rose because no fixed production costs were incurred. Interest expense increased, primarily due to imputed interest on the Novartis termination obligation.

Management said current working capital would not cover estimated cash needs for the remainder of 2012 and disclosed substantial doubt about the company’s ability to continue as a going concern. It was seeking additional capital, pursuing development of AppyScore, exploring monetization of its animal-health business and intellectual property, considering partnerships or licensing, and implementing cost controls. Without financing, it might reduce research and development or other expenses, or cease operations; any financing could significantly dilute shareholders. Planned 2012 capital expenditures were approximately $50,000.

Risks, obligations, and unusual items

• The Novartis termination obligation was $969,000 at quarter-end, with approximately $571,000 of principal due during the remainder of 2012 and $398,000 in 2013. The bank mortgage includes a balloon payment estimated at approximately $1.578 million in June 2013.
• NASDAQ had notified the company that its bid price was below the $1.00 minimum; the stated cure period ran through August 13, 2012. The company also reported that it did not meet NASDAQ’s minimum shareholders’ equity requirement and anticipated a deficiency notice.
• Two securities-related actions concerning AppyScore had pending motions to dismiss; a shareholder derivative action remained stayed. The company stated it intended to defend the claims.
• Patent impairment charges were approximately $42,000, compared with $16,000 in Q1 2011. Subsequent to quarter-end, the company granted stock options and issued 25,000 restricted shares for investor-relations services.

Important facts for investors to verify

• Confirm the filing identity: the source is AspenBio Pharma, not Riot Platforms.
• Review the company’s available financing, cash runway, and progress toward its stated 2012 funding plans.
• Check status of NASDAQ bid-price and shareholders’ equity compliance, and any potential delisting action.
• Assess AppyScore development and FDA-clearance prospects, and the potential impairment or commercialization implications.
• Review debt-payment schedules, the 2013 mortgage balloon, and developments in the disclosed litigation.